Activity of certain drugs in inducing of inflammatory myopathies with cutaneous manifestations

Expert Opinion on Drug Safety

Volumn 7, Issue 4, 2008, Pages 421-433

  Dourmishev, Lyubomir A ^a   Dourmishev, Assen L ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Adverse reactions; Inflammatory myopathies

Indexed keywords

ACETYLSALICYLIC ACID; ALFUZOSIN; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; CHLOROQUINE; COCAINE; CYCLOPHOSPHAMIDE; DIAMORPHINE; DICLOFENAC; EMETINE; ETOPOSIDE; ETRETINATE; HYDROXYCHLOROQUINE; HYDROXYUREA; IBUPROFEN; ISONIAZID; ISOTRETINOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PHENYTOIN; PRAVASTATIN; PREDNISONE; RUBELLA VACCINE; SIMVASTATIN; TAMOXIFEN; TEGAFUR; TRANILAST; TRYPTOPHAN; UNINDEXED DRUG;

AMYOPATHIC DERMATOMYOSITIS; ARTHRALGIA; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DIABETES MELLITUS; DISEASE CLASSIFICATION; DRUG ACTIVITY; DRUG WITHDRAWAL; EOSINOPHIL MYOSITIS; EOSINOPHILIA MYALGIA SYNDROME; EOSINOPHILIC FASCIITIS; GENETIC RISK; HUMAN; HYPEREOSINOPHILIA; HYPERGAMMAGLOBULINEMIA; JUVENILE DERMATOMYOSITIS; MUSCULOSKELETAL SYSTEM INFLAMMATION; MYALGIA; MYOSITIS; OVERLAP SYNDROME; PARANEOPLASTIC DERMATOMYOSITIS; PATHOGENESIS; POLYMYOSITIS; PSORIASIS; RADIATION SICKNESS; RAYNAUD PHENOMENON; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; WHOLE BODY RADIATION;

ADULT; CHILD; DERMATOMYOSITIS; EOSINOPHILIA-MYALGIA SYNDROME; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYMYOSITIS;

EID: 48749118290     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.4.421     Document Type: Review

References (170)

1. Plotz PH, Rider LG, Targoff IN, et al. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995;122:715-24
2. Dourmishev A, Dourmishev L. Dermatomyositis and drugs. Adv Exp Med Biol 1999;455:187-91
3. Beickert A, Kühne W. Dermatomyositis mit immunleucopenie, Phenothiazinschädigung. Schweiz Med Wochenschr 1960;90:132
4. Wortmann RL. Lipid-lowering agents and myopathy. Curr Opin Rheumatol 2002;14:643-7
5. Gaist D, Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a population-based study. Epidemiology 2001;12:565-9
6. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90
7. Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Lopez-Lirola A, et al. Acute rhabdomyolysis associated therapy. Arch Intern Med 2001;161:893
8. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292(Pt I):344-7, (Pt II):403-7
9. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 1991;24:959-66
10. Trueb RM, Pericin M, Winzeler B, et al. Eosinophilic myositis/ perimyositis: frequency and spectrum of cutaneous manifestations. J Am Acad Dermatol 1997;37:385-91
11. Dalakas M. Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med 1991;325:1487-98
12. Doyle DR, McCurely TL, Sergent JS. Fatal polymyositis in d-penicillamine-treated rheumatoid arthritis. Ann Intern Med 1983;98:327-30
13. Bessen LJ, Greene JB, Louie E, et al. Severe polymyositis-like syndrome associated with zudovudine therapy of AIDS and ARC. N Engl J Med 1988;318:708
14. Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990;332:1098-105
15. Dourmishev LA, Stomonjakova SR, Dourmishev AL. D-penicillamine induced polymyositis and morphea in a woman with Hashimoto thyroiditis. J Eur Acad Dermatol Venereol 2002;16:538-9
16. Schlumpf U, Bussman HU, Jerusalem F. Myositis bei chronischer polyarthritis unter d-penicillamin, medicamentos induziert? Schweiz Med Wochenschr 1981;111:29-35
17. Wright GD, Wilson C, Bell AL. D-penicillamine induced polymyositis causing complete heart block. Clin Rheunatol 1994;13:80-2
18. Fauchais AL, Iba Ba J, Maurage P, et al. Polymyositis induced or associated with lipid-lowering drugs: five cases. Rev Med Interne 2004;25:294-8
19. Mastaglia FL. Adverse effects of drugs on muscle. Drugs 1982;24:304-21
20. Sauvaget F, Piette JC, Herson S, et al. Fenofibrate-induced polymyositis. Rev Med Interne 1991;12:52
21. Fusella J, Strosberg JM. Polymyositis exacerbed by gemfibrocil. J Rheumatol 1990;17:572
22. Norman DJ, Illingworth DR, Munson J, et al. Myositis and acute renal failure in a heart transplantant recipient receiving lovastatin. N Engl J Med 1988;318:46-7
23. Pierce IR, Wysowski D, Gross TP. Myopathy and rhabdomyolysis, associated with lovastatin-gemfibrocil combination therapy. JAMA 1990;264:71-5
24. Wallace CS, Mueller BA. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann Pharmacol 1992;26:190-2
25. Bilheimer DW. Myopathy from simvastatin. Cardiology 1990;77(Suppl 4):58
26. Berland Y, Vacher Coponat H, Durand C, et al. Rhabdomyolysis with simvastatin use. Nephron 1991;57:365-6
27. Deslypere JP, Vermeulen A. Rhabdomyolysis with simvastatin. Ann Intern Med 1991;114:342
28. McDonagh J, Winocour P, Walker DJ. Musculskeletal manifestations during simvastatin therapy. Br J Rheumatol 1992;32:647-8
29. Shohaib SA. Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure. Am J Nephrol 2000;20:212-3
30. Stirling CM, Isles CG. Rhabdomyolysis due to simvastatin in a transplant patient: are some statins safer than others? Nephrol Dial Transplant s2001;15:873-4
31. Schalke BB, Schmidt B, Toyka K, et al. Pravastatin-associated inflammatory myopathy. N Engl J Med 1992;111:649-50
32. Thual N, Penven K, Chevallier JM, et al. Fluvastatin-induced dermatomyositis [Article in French]. Ann Dermatol Venereol 2005;132(12):996-9
33. Cronkright PJ, Szymaniak G. Isoniazid and rhabdomyolysis. Ann Intern Med 1989;110:945
34. Van Marle W, Woods KL. Acute hydrocortisone myopathy. BMJ 1980;281(6235):271-2
35. Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 1985;76:234-42
36. Knox AJ, Mascie-Taylor BH, Muers MF. Acute hydrocortisone myopathy in acute severe asthma. Thorax 1986;41:411-2
37. Shee CD. Risk factors for hydrocortisone myopathy in acute severe asthma. Respir Med 1990;84:229-33
38. Decramer M, Stas KJ. Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am Rev Respir Dis 1992;146:800-2
39. Shee CD. Muscle weakness after short course of steroids. Eur Respir J 2003;21:377-8
40. Nava S, Fracchia C, Callegari G, et al. Weakness of respiratory and skeletal muscles after a short course of steroids in patients with acute lung rejection. Eur Respir J 2002;20:497-9
41. Leatherman JW, Fluegel WL, David WS, et al. Muscle weakness in mechanically ventilated patients with severe asthma. Am J Respir Crit Care Med 1996;153:1686-90
42. Behbehani NA, Al-Mane F, D'Yachkova Y, et al. Myopathy following mechanical ventilation for acute asthma. The role of muscle relaxants and corticosteroids. Chest 1999;115:1627-31
43. Dalakas MC. Pharmacologic concerns of corticosteroids in the treatment of patients with immune-related neuromuscular diseases. Neurol Clin 1990;8:93-118
44. Dalakas MC. Current treatment of the inflammatory myopathies. Curr Opin Rheumatol 1994;6:595-601
45. Oddis CV. Therapy of inflammatory myopathy. Rheum Dis Clin North Am 1994;20:899-918
46. Dicken CH. Retinoids: a review. J Am Acad Dermatol 1984;11:541-52
47. McBurney EI, Rosen DA. Elevated creatine phosphokinase with isotretinoin. J Am Acad Dermatol 1983;10:528-9
48. Chen D, Rofksy HE. Elevated creatine phosphokinase and isotretinoin. J Am Acad Dermatol 1985;12:582-3
49. Jacyk WK. Elevated creatine phosphokinase levels associated with the use of etretinate. J Am Acad Dermatol 1986;15:710
50. Hodak E, Gadoth N, David M, et al. Muscle damage induced by isotretinoin. BMJ 1986;293:425
51. Ellis CN, Gilbert M, Cohen KA, et al. Increased muscle tone during etretinate therapy. J Am Acad Dermatol 1986;14:907-9
52. Hodak E, David M, Gadoth N, et al. Etretinate-induced muscle damage. Br J Dermatol 1987;116:623-6
53. Whisman JP, Espinosa RE, Kierland RR, et al. Chloroquine neuropathy. Proc Mayo Clin 1963;38:501
54. Chapman RS, Ewen WB. Chloroquine-induced myopathy. Br J Dermatol 1969;81:217-9
55. Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology 2003;42:1566-8
56. Hanissian AS, Martinez AJ, Jabbour JT, et al. Vasculitis and myositis secondary to rubella vaccination. Arch Neurol 1973;28:202-4
57. Dourmishev LA, Dourmishev AL, Schwartz RA. Dermatomyositis: cutaneous manifestations of its variants. Int J Dermatol 2002;41:625-30
58. Khattak FH, Moris IM, Branford WA. Simvastatin-associated dermatomyositis. Br J Rheumatol 1994;32:199
59. Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med 1995;25:745-6
60. Ridriguez-Gacia JI, Serrano Commino M. Lovastatin-associated dermatomyositis. Postgrad Med J 1996;72:694
61. Noël B, Cerottini JP, Panizzon RG. Atorvastatin-induced dermatomyositis. Am J Med 2001;110(8):670-1
62. al-Jubouri MA, Briston PG, Sinclair D, et al. Myxoedema revealed by simvastatin induced myopathy. BMJ 1994;308:588
63. Zuech P, Pauwels C, Duthoit C, et al. Pravastatin-induced dermatomyositis [Article in French]. Rev Med Interne 2005;26:897-902
64. Kolsi R, Bahloul Z, Hachicha J, et al. Dermatomyositie induite par la d-penicillamine au cours d'une polyarthrite rheumatoide. A propose d'un case avec revue de la literature. Rev Rheum Mal Osteo Articulaires 1992;59:341-4
65. Chapurlat R, Tebib JG, Noel E, et al. Dermatomyositis induite par la d-penicillamine au cours d'une polyarthrite rheumatoide. Rheumatologie 1995;47:203-7
66. Grob JJ, Collet AM, Bonerandi JJ. Dermatomyositis-like syndrome induced by nonsteroid anti-inflamatory agents. Dermatologica 1989;178:58-9
67. Ross NS, Hoppel CL. Partial muscle carnitine palmitoyltransferase-A deficiency. Rhabdomyolysis associated with transiently decreased muscle carnitine content after ibuprofen therapy. JAMA 1987;257:62-5
68. Curran JJ, Jamieson TW. Dermatomyositis-like syndrome associated with phenylbutazone therapy. J Rheumatol 1987;14:397-8
69. Shelley WB. Birch pollen and aspirin psoriasis. A study in salicylate hypersensitivity. JAMA 1964;189:985-8
70. Vela-Casasempere P, Borras-Blasco J, Navarro-Ruiz A. Alfuzosin-Xatral® associated dermatomyositis. Br J Rheumatol 1998; 37:1135-6
71. Woo TY, Callen JP, Voorhees JJ, et al. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984;10:592-600
72. Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 1989;16:1545-7
73. Bloom BJ, Tucker LB, Klein-Gitelman M, et al. Worsening of the rash of juvenil dermatomyositis with hydroxychloroquine thearpy. J Rheumatol 1994;21:2171-2
74. Dourmishev L, Dourmishev A. Chloquine induced psoriasis in patient with dermatomyositis [abstract]. J Eur Acad Dermatol Venereol 2000;14(S1):250
75. Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002;138:1231-3
76. Parker CW. Drug allergy. N Engl J Med 1975;292(10):511-4
77. Mackie BC, Mackie LE. Lupus erythematosus; dermatomyositis induced by sulphacetamide eye drops. Clin Exp Dermatol 1979;4:111
78. Fayolle J, Vallon C, Claudy E, et al. Dermatomyositis indute par l'isoniazide. Lyon Med 1975;223:135
79. Camus JP, Koeger AC, Nahoul K, et al. Isolated muscular tuberculosis treated with corticosteroids. Developing outbreak of dermatomyositis under rifampicin treatment. 2 cases. Ann Med Interne (Paris) 1987;138:524-6
80. Magro CM, Schaefer JT, Waldman J, et al. Terbinafine-induced dermatomyositis: a case report and literature review of drug-induced dermatomyositis. J Cutan Pathol 2008;35(1):74-81
81. Mackie B. Dermatomyositis induced by drugs. Aust J Dermatol 1966;8:249
82. Zangemeister WH, Weisner B. A progressive systemic sclerosis like disease due to anticonvulsive therapy? Fortschr Neurol Psychiatr Grenzgeb 1977;45:501-7
83. Dimachkie MM, Vriesendorp FJ, Heck KA. Phenyltoin-induced dermatomyositis: case report and literature review. J Child Neurol 1998;13:577-80
84. Dietrich LL, Bridges AJ, Albertini MR. Dermatomyositis after interferon alpha treatment. Med Oncol 2000;17:64-9
85. Gomez Rodriguez N, Zulaica Garate A. Development of dermatomyositis in a woman with rheumatoid arthritis treated with leflunomide [Article in Spanish]. An Med Interna 2005;22:300-1
86. Cotterill JA, Shapiro H. Dermatomyositis after immunization. Lancet 1978;2(8100):1158-9
87. Kass E, Straume S, Mellbye OJ, et al. Dermatomyositis associated with BCG vaccination. Scand J Rheumatol 1979;8:187-91
88. Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2006;55(6):982-4
89. Sallum AM, Kiss MH, Sachetti S, et al. Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients. Arq Neuropsiquiatr São Paulo 2002;60(4):889-99
90. Murray KJ. Juvenile dermatomyositis: advances in understanding and management. APLAR J Rheumatol 2003;6:50-63
91. Rider LG, Shamim E, Okada S, et al. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Arthritis Rheum 1999;42(6):1285-90
92. Askari A, Vignos PJ, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med 1976;61:485-92
93. Yaszici Y, Kagen LJ. The association of malignancy with myositis. Curr Opin Rheumatol 2000;12:498-500
94. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermato-myositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001;85:41-5
95. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100
96. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. Ann Intern Med 2001;134:1087-95
97. Richard M, Truchetet F, Friedel J, et al. Skin lesions simulating chronic dermatomyositis during long term hydroxyurea therapy. J Am Acad Dermatol 1989;21:797-9
98. Rocamora V, Puig L, Alomar A. Dermatomyositis-like eruption following hydroxyurea therapy. J Eur Acad Dermatol Venereol 2000;14:227-8
99. Marie I, Joly P, Levesque H, et al. Pseudo-dermatomyositis as a complication of hydroxyurea therapy. Clin Exp Rheumatol 2000;18:536-7
100. Ruiz-Genao DP, Sanz-Sanchez T, Bartolome-Gonzalez B, et al. Dermatomyositis-like reaction induced by chemotherapeutical agents. Int J Dermatol 2002;41:885-7
101. Krishnan K, Adams P, Silveira S, et al. Therapy-related acute myeloid leukaemia following immunosuppression with azathioprine for polymyositis. Clin Lab Haematol 1994;16:285-9
102. Arnold JA, Ranson SA, Abdalla SH. Azathioprine-associated acute myeloid leukaemia with trilineage dysplasia and complex karyotype: a case report and review of the literature. Clin Lab Haematol 1999;21:289-92
103. Roddy E, Couriney PA, Morris A. Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology 2002;41:1194-5
104. Kirby B, Gibson LE, Rogers S, et al. Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis. Clin Exp Dermatol 2000;25:256-7
105. Harris AL, Smith IE, Snaith M. Tamoxifen-induced tumor regression associated with dermatomyositis. BMJ 1982;284:1674
106. Akiyama C, Osada A, Sou K, et al. A case of dermatomyositis triggered by tegafur. Acta Derm Venereol 1997;77:490
107. Monk BL, Pembroke AC. Dermatomyositis after radiotherapy. Br J Dermatol 1983;S24:103
108. Kamel OW, van de Rijn M, Weiss LM, et al. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317-21
109. Bittar B, Rose CD. Early development of Hodgkin's lymphoma in association with the use of methotrexate for the treatment of dermatomyositis. Ann Rheum Dis 1995;54:607-8
110. Chai C, White WL, Shea CR, et al. Epstein Barr virus-associated lymphoproliferative disorders primarily involving the skin. J Cutan Pathol 1999;26:242-7
111. Callen JP. Dermatomyositis and multiple malignancies in a patient treated with methotrexate. J Surg Oncol 1983;24:113-6
112. Senet P, Aractingi S, Porneuf M, et al. Hydroxyurea-induced dermatomyositis-like eruption. Br J Dermatol 1995;133:455-9
113. Bahadoran P, Castanet J, Lacour JP, et al. Pseudo-dermatomyositis induced by long-term hydroxyurea therapy: report of two cases. Br J Dermatol 1996;134:1161-3
114. Suehiro M, Kishimoto S, Wakabayashi T, et al. Hydroxyurea dermatopathy with a dermatomyositis-like eruption and a large leg ulcer. Br J Dermatol 1998;139:748-9
115. Velez A, Lopez-Rubio F, Moreno J-C. Chronic hydroxyurea-induced dermato-myositis-like eruption with severe dermal elastosis. Clin Exp Dermatol 1998;23:94-5
116. Dacey MJ, Callen JP. Hydroxyurea-induced dermatomyositis-like eruption. J Am Acad Dermatol 2003;48:439-41
117. Vassallo C, Passamonti F, Merante S, et al. Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Exp Dermatol 2001;26:141-8
118. Oskay T, Kutluay L, Ozyilkan O. Dermatomyositis-like eruption after long-term hydroxyurea therapy for polycythemia vera. Eur J Dermatol 2002;12:586-8
119. Varma S, Lanigan SW. Dermatomyositis-like eruption and leg ulceration caused by hydroxyura in a patient with psoriasis. Clin Exp Dermatol 1999;24:164-6
120. Oh ST, Lee DW, Lee JY, et al. Hydroxyurea-induced melanonychia concomitant with a dermatomyositis-like eruption. J Am Acad Dermatol 2003;49:339-41
121. Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermatopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol 1997;36:178-82
122. Bouldouyre MA, Avril MF, Gaulier A, et al. Association of cutaneous side-effects of hydroxyurea and neuroendocrine carcinoma. Eur J Dermatol 2005;15:268-70
123. Nishikai M, Funatsu Y, Homa M. Monoclonal gammapathy, penicillamine-induced polymyostis and systemic sclerosis. Arch Dermatol 1974;110:253-5
124. Dunand M, Lobrinus JA, Spertini O, et al. Eosinophilic perimyositis as the presenting feature of a monoclonal T-cell expansion. Muscle Nerve 2005;31(5):646-51
125. Krahn M, Lopez de Munain A, Streichenberger N, et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol 2006;59(6):905-11
126. Arase S, Kato S, Nakanishi H, et al. Eosinophilic polymyositis induced by tranilast. J Dermatol 1990;17:182-6
127. Koch-Weser J, Sidel VW, Dexter M, et al. Adverse reactions to sulfisoxazole, sulfamethoxazole and nitrofurantoin. Arch Intern Med 1971;128:399-404
128. Ellman L, Miller L, Rappeport J. Leucophoresis therapy of hypereosinophilic disrorder. JAMA 1974;230:1004-5
129. Boman BL. L-Tryptophan: a rational anti-depressant and a natural hypnotic? Aust N Z J Psychiatry 1988;22:83-97
130. Hertzman PA, Blevins WL, Mayer J, et al. Association of the eosinophilia-myalgia syndrome with ingestion of tryptophan. N Engl J Med 1990;322:869-73
131. Medsger TA. Tryptophan-induced eosinophilia-myalgia syndrome. N Engl J Med 1990;322:926-8
132. Blevins WL, Hertzman P, Ting M, et al. Eosinophylia-myalgia syndrome - New Mexico. MMWR 1989;38:765-7
133. Centers for Disease Control. Eosinophylia-myalgia syndrome and L-tryptophan-containing products - New Mexico, Minesota, Oregon, and New York, 1989. MMWR 1989;38:785-8
134. Eidson M, Philen RM, Sewell CM, et al. L-tryptophan and eosinophilia-myalgia syndrome in New Mexico. Lancet 1990;335:645-8
135. Tabuenca JM. Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet 1981;2:567-8
136. Toxic Epidemic Syndrome Study Group. Toxic epidemic syndrome, Spain, 1981. Lancet 1982;2:697-702
137. Kilbourne EM, Rigau-Perez JG, Heath CW Jr, et al. Clinical epidemiology of toxic-oil syndrome. N Engl J Med 1983;309:1408-14
138. Phleps RG, Fleischmajer R. Clinical, pathologic, and immunopathologic manifestations of the toxic oil syndrome. J Am Acad Dermatol 1988;18:313-24
139. Sanchez-Porro Valades P, Posada de la Paz M, de Andres Copa P, et al. Toxic oil syndrome: survival in the whole cohort between 1981 and 1995. J Clin Epidemiol 2003;56:701-8
140. Diggle GE. The toxic oil syndrome: 20 years on. Int J Clin Pract 2001;55:371-5
141. Centers for Disease Control. Clinical spectrum of eosinophylia-myalgia syndrome-California. MMWR 1990;39:89-91
142. Kaufman LD, Seidman RJ, Phillips ME, et al. Cutaneous manifestations of the l-tryptophan-associated eosinophilia-myalgia syndrome: a spectrum of sclerodermatous skin disease. J Am Acad Dermatol 1990;23:1063-9
143. Cotsarelis G, Werth V. Tryptophan-induced eosinophilic fasciitis. J Am Acad Dermatol 1990;23:938-40
144. Senff H, Köllner A, Engelmann L, et al. L-tryptophan-induziertes eosinophilie-myalgie-syndrome unter dem bild einer diffusen fasziitis mit eosinophilie-shulman-syndrom. Hautarzt 1990;41:578-82
145. Connolly SM, Quimby SR, Griffing WL, et al. A possible explanation of the eosinophilia-myalgia syndrome. J Am Acad Dermatol 1990;23:451-7
146. Hertzman PA, Blevins WL, Mayer J, et al. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med 1990;322:869-73
147. Shulman LE. Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome? J Rheumatol 1974;S1:46
148. Martin R, Duffy J. Eosinophilic fasciitis associated with l-tryptophan (LT) use: a case control study. Arthritis Rheum 1990;S33:R30
149. Gordon ML, Lebwohl MG, Phelps RG, et al. Eosinophilic fasciitis associated with tryptophan ingestion: a manifestation of eosinophilia myalgia syndrome. Arch Dermatol 1991;127:217-20
150. Fujimoto M, Sato S, Ihn H, et al. Serum aldolase level is a useful indicator of disease activity in eosinophilic fasciitis. J Rheumatol 1995;22:563-5
151. Buchanan RR, Gordon DA, Muckle TJ, et al. The eosinophilic fasciitis syndrome after phenytoin (dilantin) therapy. J Rheumatol 1980;7:733-6
152. Seaman JM, Goble M, Madsen L, et al. Fasciitis and polyarthritis during antituberculous therapy. Arthritis Rheum 1985;28:1079-84
153. Lee P. Eosinophilic fasciitis - new association and current perspectives. J Rheumatol 1981;8:6-8
154. Wilson CL, Bradlow A, Wonjarowska F. Cutaneous problems with drug therapy in rheumatoid arthritis. Int J Dermatol 1991;30:148-9
155. Pachman LM, Liotta-Davis MR, Hong DK, et al. TNFα-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor α, disease duration, and pathologic calcifications. Arthritis Rheum 2000;43:2368-77
156. Werth VP, Callen JP, Ang G, et al. Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol 2002;119(3):617-20
157. Kubo M, Ihn H, Yazawa N, et al. Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis. J Invest Dermatol 1999;112:711-5
158. Hess E. Drug-related lupus. N Engl J Med 1988;318:1460-2
159. Price EJ, Venables PT. Drug-induced lupus. Drug Saf 1995;12:283-90
160. Klarskov K, Johnson KL, Benson LM, et al. Structural characterization of a case-implicated contaminant, "Peak X," in commercial preparations of 5-hydroxytryptophan. J Rheumatol 2003;30:89-95
161. Varga J, Kahari VM. Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and a related fibrosing disorders. Curr Opin Rheumatol 1997;8:562-70
162. Fonseca E, Solis J. Mast cells in the skin: progressive systemic sclerosis and the toxic oil syndrome. Ann Intern Med 1985;102:864-5
163. Pincus SH, Ramesh K, Wyler D. Eosinophils stimulate fibroblast DNA synthesis. Blood 1987;70:572-4
164. Jacobson TA. Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. Curr Atheroscler Rep 2001;3:373-82
165. Worz CR, Bottorff M. The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins. Expert Opin Pharmacother 2001;2:1119-27
166. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001;57:357-64
167. Sinzinger H, Lupattelli G, Chehne F. Increased lipid peroxidation in a patient with CK-elevation and muscle pain during statin therapy. Atherosclerosis 2000;153:255-6
168. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83:490-500
169. Kovacs SO, Kovacs SC. Dermatomyositis. J Am Acad Dermatol 1998;39:899-920
170. Kamenska V, Dourmishev L, Dourmishev A, et al. Dermatomyositis activity of drug chemicals: a QSAR application. Drug Res 2006;56(12):856-65